Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H21FN2O.2ClH |
Molecular Weight | 421.335 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.FC1=CC=C(C=C1)C2=CN=CC(CNC[C@H]3CCC4=C(O3)C=CC=C4)=C2
InChI
InChIKey=ANXOJXYTTDGHAJ-GHVWMZMZSA-N
InChI=1S/C22H21FN2O.2ClH/c23-20-8-5-17(6-9-20)19-11-16(12-24-14-19)13-25-15-21-10-7-18-3-1-2-4-22(18)26-21;;/h1-6,8-9,11-12,14,21,25H,7,10,13,15H2;2*1H/t21-;;/m1../s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C22H21FN2O |
Molecular Weight | 348.4133 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Sarizotan (also known as EMD-128,130), a chromane derivative that was developed as a selective 5-HT1A receptor agonist and D2 receptor antagonist. Experiments on animal models have shown that the drug effectively suppressed levodopa-induced dyskinesia in primate and rodent models of Parkinson's disease, and tardive dyskinesia in a rodent model. Sarizotan participated in phase II/III clinical trials in the treatment of dyskinesia associated with the dopaminergic treatment of Parkinson's disease. However, further development for this disease was discontinued by Merk, because phase III did not confirm earlier Phase II findings. On July 14, 2015, Newron Pharmaceuticals, research, and development company focused on the novel central nervous system (CNS) and pain therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sarizotan for treatment of Rett syndrome. Besides, the drug now is an ongoing clinical trial phase II/III to investigate its the tolerability and efficacy in reducing respiratory abnormalities in Rett Syndrome.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Drugs in development for Parkinson's disease. | 2004 Jul |
|
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. | 2006 Sep |
|
Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. | 2006 Sep |
|
[Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy]. | 2007 Jul |
|
Placebo influences on dyskinesia in Parkinson's disease. | 2008 Apr 15 |
|
Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity. | 2010 Nov 16 |
|
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00105508
Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:11:03 GMT 2023
by
admin
on
Sat Dec 16 11:11:03 GMT 2023
|
Record UNII |
4D56ANR2VD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4D56ANR2VD
Created by
admin on Sat Dec 16 11:11:03 GMT 2023 , Edited by admin on Sat Dec 16 11:11:03 GMT 2023
|
PRIMARY | |||
|
m9782
Created by
admin on Sat Dec 16 11:11:03 GMT 2023 , Edited by admin on Sat Dec 16 11:11:03 GMT 2023
|
PRIMARY | Merck Index | ||
|
177976-12-4
Created by
admin on Sat Dec 16 11:11:03 GMT 2023 , Edited by admin on Sat Dec 16 11:11:03 GMT 2023
|
PRIMARY | |||
|
68742912
Created by
admin on Sat Dec 16 11:11:03 GMT 2023 , Edited by admin on Sat Dec 16 11:11:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |